400-920-2911 sales@csnpharm.cn
CAS No.: 1313883-00-9
Synonyms: ARQ-092 hydrochloride;Miransertib;Miransertib HCl
ARQ 092 is a pan-Akt inhibitor with IC50 values of 5nM, 4.5nM and 16nM for Akt1, Akt2 and Akt3, respectively, through blocking membrane translocation of inactive AKT and even dephosphorylating the membrane-associated active form.
规格 | 价格 | 促销价格 | 库存 | 数量 |
---|
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT02594215 | Proteus Syndrome | Phase 1 | Active, not recruiting | December 1, 2025 | United States, Maryland ... more >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Collapse << |
NCT03317366 | - | - | - | - | - |
NCT03094832 | Proteus Syndrome ... more >> PIK3CA-Related Overgrowth Spectrum (PROS) Collapse << | Phase 1 Phase 2 | Recruiting | June 2020 | United States, Massachusetts ... more >> Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: ArQule 781-994-0300 ClinicalTrials@arqule.com Italy Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele" Withdrawn Catania, Italy Fondazione Policlinico Universitario Agostino Gemelli Recruiting Roma, Italy, 00168 Contact: ArQule 781-994-0300 ClinicalTrials@arqule.com Ospedale Bambino Gesu Recruiting Rome, Italy Contact: ArQule 781-994-0300 ClinicalTrials@arqule.com Collapse << |
实验方案
技术信息
CAS号 | 1313883-00-9 | 储存条件 |
|
|||||||||||||
分子式 | C27H25ClN6 | 运输 | 蓝冰 | |||||||||||||
分子量 | 468.98 | 别名 | ARQ-092 hydrochloride;Miransertib;Miransertib HCl;ARQ092 HCl;ARQ-092 | |||||||||||||
溶解度 |
|
动物实验配方 |
|